1. Ahrnsbrak, R., Bose, J., Hedden, S. L., Lipari, R. N., & Park-Lee, E. (2017). Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on drug use and health. In Center for Behavioral Health Statistics and Quality. Rockville, MD: Substance Abuse and Mental Health Services Administration.
2. Ailey, S. H., Miller, A. M., Heller, T., & Smith, E. V. (2006). Evaluating an interpersonal model of depression among adults with down syndrome. Research and Theory for Nursing Practice, 20(3), 229–246.
3. Aman, M. G., & Singh, N. N. (1991). Pharmacological intervention. In J. L. Matson & J. A. Mulick (Eds.), Handbook of mental retardation., 2nd ed. (pp. 347–372). Retrieved from
http://search.ebscohost.com/login.aspx?direct=true&db=psyh&AN=1991-97816-023&site=ehost-live
4. Aman, M. G., Van Bourgondien, M. E., Wolford, P. L., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child & Adolescent Psychiatry, 34(12), 1672–1681.
https://doi.org/10.1097/00004583-199512000-00018
5. Austin, K. L., Hunter, M., Gallagher, E., & Campbell, L. E. (2018). Depression and anxiety symptoms during the transition to early adulthood for people with intellectual disabilities: Depression and anxiety in young adults with ID. Journal of Intellectual Disability Research, 62(5), 407–421.
https://doi.org/10.1111/jir.12478